Drug news
Erbitux (Merck Serono) fails EXPAND trial for Gastric Cancer
Merck Serono has announced the outcome of the Phase III clinical trial EXPAND, which assessed Erbitux (cetuximab) in combination with cisplatin and capecitabine as a 1st-line treatment for patients with advanced Gastric Adenocarcinoma including adenocarcinoma of the gastro-esophageal junction. The trial did not meet its primary endpoint of extending the length of time that patients live without their disease getting worse (progression-free survival), as determined by independent review.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.